These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28669130)

  • 81. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials.
    Zheng J; Song W
    Medicine (Baltimore); 2017 Jul; 96(28):e7151. PubMed ID: 28700465
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
    van den Hoogen MW; Hoitsma AJ; Hilbrands LB
    Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date.
    Heilman RL; Mazur MJ; Reddy KS
    Drugs; 2010 May; 70(7):793-804. PubMed ID: 20426494
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation.
    Sageshima J; Ciancio G; Guerra G; Gaynor JJ; Cova D; Zarak A; Chen L; Mattiazzi A; Kupin W; Roth D; Hanson L; Livingstone AS; Ruiz P; Burke GW
    Transpl Immunol; 2011 Sep; 25(2-3):104-11. PubMed ID: 21784152
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Delayed allograft inflammation following alemtuzumab induction for kidney transplantation.
    Heilman RL; Khamash HA; Smith ML; Chakkera HA; Moss AA; Reddy KS
    Clin Transplant; 2013; 27(5):772-80. PubMed ID: 23924146
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial.
    Carrier M; Leblanc MH; Perrault LP; White M; Doyle D; Beaudoin D; Guertin MC
    J Heart Lung Transplant; 2007 Mar; 26(3):258-63. PubMed ID: 17346628
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.
    Riad S; Jackson S; Chinnakotla S; Verghese P
    Pediatr Transplant; 2021 Aug; 25(5):e13928. PubMed ID: 33314638
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
    Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
    Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study.
    Demeter J; Buck B; Zimmerman A; Mitro G; Rees M; Ortiz J
    Exp Clin Transplant; 2019 Dec; 17(6):739-748. PubMed ID: 29633926
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
    Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
    Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
    Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
    Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.
    Hafeez MS; Haq MU; Bakhthiyar SS; Azhar K; Awan AAY; Ramana Murthy BV; Abbas R
    Transpl Immunol; 2022 Dec; 75():101733. PubMed ID: 36347493
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients.
    Niu Q; Mendoza Rojas A; Dieterich M; Roelen DL; Clahsen-van Groningen MC; Wang L; van Gelder T; Hesselink DA; van Besouw NM; Baan CC
    Front Immunol; 2020; 11():1972. PubMed ID: 32983131
    [No Abstract]   [Full Text] [Related]  

  • 99. Lymphocyte depletion and risk of acute rejection in renal transplant recipients at increased risk for delayed graft function.
    Ravindra KV; Sanoff S; Vikraman D; Zaaroura A; Nanavati A; Sudan D; Irish W
    Am J Transplant; 2019 Mar; 19(3):781-789. PubMed ID: 30171800
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity.
    Stauch D; Dernier A; Sarmiento Marchese E; Kunert K; Volk HD; Pratschke J; Kotsch K
    PLoS One; 2009; 4(3):e4709. PubMed ID: 19266059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.